The board of GenVec Inc. has voted to liquidate and dissolve the struggling Gaithersburg biotech, it announced Tuesday in a securities filing.
The move follows a string of setbacks for GenVec, which three years ago saw its lead pancreatic cancer drug candidate, TNFerade, fail in late-stage trials. In 2011, longtime CEO Paul Fischer announced his retirement from the company.
{iframe}http://www.bizjournals.com/washington/blog/techflash/2013/05/genvec-board-votes-to-dissolve-company.html{/iframe}